血管加压素及其类似物在分布性休克中的肾脏结局:随机试验的系统评价与Meta分析
该系统评价与Meta分析检索MEDLINE、Embase、Cochrane Central和Clinicaltrials.gov,纳入17项随机临床试验共2833例成人分布性休克患者,其中11项研究(2691例)进入定量合并。与其它血管加压药相比,使用血管加压素及其类似物者肾脏替代治疗需求降低(OR 0.59,95%CI 0.37-0.92,P=0.02,I²=49%),急性肾损伤发生率降低(OR 0.58,95%CI 0.37-0.92,P=0.02,I²=63%)。无急性肾损伤天数因研究数量少且异质性极大未行合并。总体证据质量为低至中等,结论需谨慎解读。
要点
- 成人分布性休克患者使用血管加压素及其类似物,肾脏替代治疗需求较其它血管加压药降低(OR 0.59,95%CI 0.37-0.92,P=0.02,I²=49%)。
- 同一人群急性肾损伤发生率降低(OR 0.58,95%CI 0.37-0.92,P=0.02,I²=63%),但异质性明显,结果需谨慎解读。
- 无急性肾损伤天数未行定量合并,因研究数量少且异质性极大。
- 总体证据质量为低至中等,且结果受高偏倚风险证据支持。
- 该系统评价已在PROSPERO注册(CRD42017054324),共纳入17项随机试验、2833例患者。
适用人群与场景
- 成人分布性休克患者,纳入比较血管加压素及其类似物与其它血管加压药并报告肾脏结局的随机临床试验。
研究设计与关键结果
- 系统评价与Meta分析,检索MEDLINE、Embase、Cochrane Central和Clinicaltrials.gov,初筛3026篇文献,全文审阅30篇,最终17项研究符合纳入标准共2833例,其中11项研究(2691例)适合定量Meta分析。
- 与其它血管加压药相比,血管加压素及其类似物组肾脏替代治疗需求降低:OR 0.59(95%CI 0.37-0.92),P=0.02,I²=49%。
- 血管加压素及其类似物组急性肾损伤发生率降低:OR 0.58(95%CI 0.37-0.92),P=0.02,I²=63%。
- 无急性肾损伤天数数据未行合并,因研究数量少且异质性极大。
- 总体证据质量为低至中等。
证据类型、等级与局限
- 证据类型:随机临床试验的系统评价与Meta分析,采用GRADE方法总结证据质量,总体证据质量为低至中等。
- 采用随机效应模型(Mantel-Haenszel加权),异质性以I²>50%定义为显著异质性。
- 作者结论指出这些结果受高偏倚风险证据支持,并因异质性过大需谨慎解读。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在成人分布性休克患者中,使用血管加压素及其类似物可能与非使用其它血管加压药者相比降低肾脏替代治疗需求和急性肾损伤发生率,但作者指出结果需谨慎解读且受高偏倚风险证据支持。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To systematically review the literature and synthesize evidence concerning the effects of vasopressin and its analogs compared with other vasopressors in distributive shock, focusing on renal outcomes.
DATA SOURCES: We performed a systematic review in MEDLINE, Embase, Cochrane Central, and Clinicaltrials.gov databases.
STUDY SELECTION: Randomized clinical trials that compared vasopressin and its analogs with other vasopressors and reported renal outcomes in adult patients with distributive shock.
DATA EXTRACTION: Paired reviewers independently screened citations, conducted data extraction and assessed risk of bias. Three prespecified subgroup analyses were conducted. Three main outcomes related to acute renal failure were analyzed: the need for renal replacement therapy, acute kidney injury incidence, and acute kidney injury-free days. I test was used to evaluate heterogeneity between studies. Substantial heterogeneity was defined as I greater than 50%. A random-effects model with Mantel-Haenszel weighting was used for all analyses. Heterogeneity was explored using subgroup analysis. The quality of evidence for intervention effects was summarized using Grading of Recommendations Assessment, Development, and Evaluation methodology. This study was registered in the PROSPERO database (CRD42017054324).
DATA SYNTHESIS: Three-thousand twenty-six potentially relevant studies were identified, and 30 articles were reviewed in full. Seventeen studies met the inclusion criteria, including a total of 2,833 individuals. Of these, 11 studies (2,691 individuals) were suitable for quantitative meta-analysis. Overall, the evidence was of low to moderate quality. Patients who received vasopressin and its analogs had a reduced need for renal replacement therapy (odds ratio, 0.59 [0.37-0.92]; p = 0.02; I = 49%) and a lower acute kidney injury incidence (odds ratio, 0.58 [0.37-0.92]; p = 0.02; I = 63%). These results should be interpreted with caution, due to excessive heterogeneity. Acute kidney injury-free data was not pooled, since the small number of studies and extreme heterogeneity.
CONCLUSIONS: In patients with distributive shock, vasopressin and its analogs use is associated with a reduced need for renal replacement therapy and lower acute kidney injury incidence. These results are supported by high risk of bias evidence.
参考来源
- Nedel WL, Rech TH, Ribeiro RA, et al. Renal Outcomes of Vasopressin and Its Analogs in Distributive Shock: A Systematic Review and Meta-Analysis of Randomized Trials. Crit Care Med. 2019. PMID: 30303842. doi:10.1097/CCM.0000000000003471
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。